{"id":"W4320717208","doi":"10.1159/000529636","title":"Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Bayer Yakuhin; Chugai Pharmaceutical; Sirtex Medical; Ipsen; Servier; Ono Pharmaceutical; Eisai; Sanofi; Bayer HealthCare; Incyte; EA Pharma Co., Ltd.; Gilead Sciences; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Hepatocellular carcinoma; Term (time); Oncology; Internal medicine; Cancer; Immunotherapy; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002198867,0.0004422525,0.0006472695,0.00010975,0.0002792226,0.00005982177,0.0002652819,0.0002158599,0.003396897],"category_scores_gemma":[0.00005471604,0.0003033414,0.0006295028,0.0004027647,0.0001012822,0.0001521539,0.00006404699,0.0002605414,0.000285836],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001777361,"about_ca_system_score_gemma":0.0003713597,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005900247,"about_ca_topic_score_gemma":0.0001130088,"domain_scores_codex":[0.997686,0.000102708,0.0004400023,0.0007049253,0.0004334263,0.0006329214],"domain_scores_gemma":[0.9983451,0.0003789279,0.0001615574,0.0007099747,0.0001673889,0.0002370744],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3254165,0.001397718,0.4149203,0.0002314455,0.002115268,0.001500746,0.008445764,0.000002699364,0.03517129,0.00009977371,0.02827945,0.1824191],"study_design_scores_gemma":[0.6432809,0.008317336,0.02487554,0.0002345383,0.001885175,0.00002618162,0.0004844099,0.01046233,0.1474977,0.0005207674,0.16125,0.001165257],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9813149,0.0102326,0.00006041893,0.001236211,0.001576179,0.004447715,0.0006154815,0.0002226043,0.0002938964],"genre_scores_gemma":[0.982091,0.001605717,0.00009083009,0.001242616,0.001956193,0.002495089,0.001045225,0.0001148358,0.009358548],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3900448,"threshold_uncertainty_score":0.9999419,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09416067897063918,"score_gpt":0.321198574962859,"score_spread":0.2270378959922199,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}